Clinical trials: Cognitive Impairments
Healthy, Alzheimer Disease
A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease
The purpose of this study is to investigate changes of cerebral spinal fluid (CSF) proteins over time using continuous CSF sampling for 36 hours in elderly healthy volunteers and volunteers with mild cognitive impairment or…
- Trial name
- NCT01436188
- Testing
- Standard CSR sampling procedure, Alternate frequency CSR sampling procedure, Standard frequent CSR sampling procedure with 800 mg ibuprofen
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease (AD)
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1707 in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD for 26 weeks.
- Trial name
- NCT06114745
- Testing
- SHR-1707 injection
- Where
- 3 sites in Australia
- Volunteers
- 2 people
- Sponsor
- Atridia Pty Ltd.
Down Syndrome
A Study of ACI-24 in Adults With Down Syndrome
This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.
- Trial name
- NCT04373616
- Testing
- ACI-24
- Sponsor
- AC Immune SA
Multiple Sclerosis, Mild Cognitive Impairment
Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms
CT-100 is a platform that provides an interactive, software based therapeutic component that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital…
- Conditions
- Multiple Sclerosis, Mild Cognitive Impairment, Cancer
- Trial name
- NCT05438147
- Testing
- CT-100 DiNaMo, Care-as-Usual
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Click Therapeutics, Inc.
Mild Cognitive Impairment
Effect of Consuming a Mixture of Extracts and DHA on the Mild Cognitive Impairment
The objective of this trial is to evaluate the effect of the consumption of a mixture of extracts and DHA on the mild cognitive impairment.
- Trial name
- NCT06254040
- Testing
- mixture of extracts and DHA
- Where
- Spain
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Alzheimer Disease, Dementia
Reducing Dementia Risk With Digital Health Coaching
The Digital Cognitive Multi-domain Alzheimer's Risk Velocity (DC MARVEL) study is a 2-year randomized controlled trial on dementia prevention.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- DC-MARVEL (NCT04559789)
- Testing
- MindMate + Health Coaching, Health Education
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Neurotrack Technologies, Inc.
Schizophrenia
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia
The purpose of this study is to test a new computerized training program as well as to find out whether the computer training might help people who have schizophrenia.
- Trial name
- TARA (NCT01773239)
- Testing
- TARA computer-based exercises
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Posit Science Corporation
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimers Disease
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease
The goal of this study is to evaluate whether use of the PrecivityAD2 blood biomarker assay with early result disclosure along with discretionary Precivity-ApoE proteotype testing will shorten the time to Alzheimer's Disease or…
- Trial name
- ADELAIDE (NCT06856681)
- Testing
- PrecivityAD2 - Early Testing, PrecivityAD2 - Delayed Testing
- Sponsor
- C2N Diagnostics
Cognitive Disorders
Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects
This is a First Time in Human Study to assess the safety, tolerability and pharmacokinetics of single doses of GSK1034702 in healthy subjects.
- Trial name
- NCT00743405
- Testing
- GSK1034702
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients…
- Trial name
- NCT00857532
- Testing
- florbetapir F 18
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- REPHRASE (NCT05107882)
- Where
- 7 sites in United States, Canada
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- Optina Diagnostics Inc.
Traumatic Brain Injury
Traumatic Brain Injury Peripheral Nerve Study
Peripheral nerve stimulation for the treatment of sequelae due to traumatic brain injury. This study will specifically examine patients with mild traumatic brain injury (TBI) who have persistent cognitive impairments lasting one…
- Trial name
- TBI (NCT01588691)
- Testing
- Eon-mini IPG (implantable pulse generator)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Abbott Medical Devices
Learning Disorder, Specific, Learning Disability
Examining the Medium-term Effect on Non Inferiority of the Previous Training With the DMD Poppins Clinical for Cognitive, Musical Training in Addition to Bi-monthly Speech and Reading Therapy on Reading Writing Abilities of Pediatric Patients With SLD Reading VS Control Group
Poppins-02-b is an observational follow-up study examining the medium-term effect on non-inferiority of the previous training with the digital medical device (DMN) Poppins Clinical for cognitive and musical training in addition…
- Conditions
- Learning Disorder, Specific, Learning Disability, Specific Learning Disorder, With Impairment in Reading, Dyslexia
- Trial name
- POPPINS-02-B (NCT06902610)
- Testing
- Poppins Clinical
- Where
- 2 sites in France
- Volunteers
- 306 people
- Sponsor
- Poppins
Cognitive Change, Mood
Turmeric for Memory Impairment and Cognition
The objective of the study is to test the capacity of acute and chronic supplementations of Turmipure GOLD® to improve cognitive performance in healthy aging
- Conditions
- Cognitive Change, Mood, Stress
- Trial name
- TURMEMIC (NCT04860050)
- Testing
- Turmipure Gold®
- Where
- Ireland
- Volunteers
- 568 people, healthy volunteers welcome
- Sponsor
- Givaudan France Naturals
Alzheimer's Disease
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
Subjects will be adults aged 50 to 85 years who have subjective memory complaints and mild cognitive impairment or mild dementia due to Alzheimer's disease (AD).
- Trial name
- NCT01600859
- Testing
- E2609
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eisai Inc.
Alzheimer's Type Dementia
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.
- Trial name
- NCT01276353
- Testing
- E2020
- Where
- 11 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Dementia, Mild Cognitive Impairment
Prospective Research in Memory Clinics (PRIME)
The purpose of the PRIME Study is to examine the current management and outcomes of patients with mild cognitive impairment or dementia.
- Trial name
- NCT00297271
- Testing
- Current treatment practice of each participating physician
- Where
- 9 sites in Australia
- Volunteers
- 970 people
- Sponsor
- Janssen-Cilag Pty Ltd
Aging, Cognitive Decline
Impact of a Novel Brain Longevity Supplement Containing the Postbiotic Urolithin A (Mitopure) on Cognitive Function and Related Health Outcomes
This is a parallel group, randomized, double-blind, placebo-controlled clinical study assessing the safety and effects of a novel nutritional product on self-reported cognitive function and health in adults that reside in the…
- Conditions
- Aging, Cognitive Decline, Brain Fog, Cognitive Function
- Trial name
- CLARITY (NCT07060898)
- Testing
- Active Product
- Where
- United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Amazentis SA
Mild Cognitive Impairment, Mild Dementia
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
- Trial name
- NCT04148391
- Testing
- NYX-458
- Where
- 26 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aptinyx